+34 620 10 75 37info@nanbiosis.com

News

nanbiosis news

Atomic Force Microscopy (AFM): Principles, Modes, and Emerging Applications in Nanotechnology and Biomedicine

Discover how Atomic Force Microscopy (AFM) provides nanometric precision in imaging, mechanical analysis, and electrochemical characterization of surfaces. Explore real-world applications in nanotech, semiconductors, and biomedicine.

Introduction

Atomic Force Microscopy (AFM) is a cutting-edge surface characterization technique that enables researchers to explore surfaces with nanometer-scale precision. Unlike optical or electron microscopes, AFM uses a mechanical probe to scan and measure the surface topography, material properties, and interactions at the atomic level.

The versatility of AFM allows it to operate in various environments, including air, vacuum, and liquids. This makes it ideal for a wide range of applications, from materials science to biomedicine. It provides both qualitative imaging and quantitative analysis of topography, mechanical elasticity, electrical properties, and more.

As advanced as it is adaptable, AFM enables the development of new semiconductors, high-performance polymers, bio-compatible coatings, and real-time biological measurements at the molecular scale. With the integration of specialized modes and AI-driven software, the Bruker Dimension Icon-PT AFM, for example, brings even greater efficiency and precision to modern nanoscale research.

Understanding the fundamentals of AFM

Atomic Force Microscopy was invented in 1986 by Binnig, Quate, and Gerber. Its original design has since evolved into a family of techniques that share one common feature: the interaction between a sharp probe tip and a surface.

The basic components of an AFM system include:

  • Cantilever and Tip: A nanometer-scale tip mounted on a flexible cantilever that interacts with the sample.
  • Laser and Photodetector: A laser beam reflects off the back of the cantilever and onto a photodetector, tracking vertical displacement.
  • Piezoelectric Scanner: Controls the movement of the sample or the probe with sub-nanometer accuracy.
  • Feedback System: Maintains a constant force or height to allow precise mapping of the surface.

AFM does not rely on light or electrons to generate images. Instead, it uses force interactions, such as van der Waals, electrostatic, or capillary forces, to sense the features of the surface. This makes it especially suitable for non-conductive samples, unlike SEM or TEM.

Additionally, AFM can function in air, liquids, or controlled gas environments, enabling real-time biological and chemical analysis under near-physiological conditions. This environmental adaptability is a major advantage in biosanitary research.

AFM working modes explained

Atomic Force Microscopy offers multiple operational modes, each designed for specific material types and analytical goals.

Contact Mode

In contact mode, the probe remains in constant contact with the surface as it scans. This mode provides high-resolution imaging but can be invasive, especially for soft or biological samples. It is best suited for hard, stable surfaces such as metals, glass, and ceramics.

Tapping Mode (Intermittent contact)

Tapping mode oscillates the cantilever at its resonance frequency and gently touches the surface during each cycle. This reduces lateral forces and sample damage, making it ideal for imaging soft polymers, biological tissues, and loosely bound nanoparticles.

Non-contact Mode

In non-contact mode, the cantilever vibrates near the surface without touching it. It detects attractive van der Waals forces, offering the least invasive method for delicate or loosely bound surface features.

Other advanced Modes

In addition to the former, there are advanced AFM modes worth mentioning, such as PeakForce QNM®, KPFM, and TUNA.

  • PeakForce QNM®: Measures mechanical properties (modulus, adhesion, deformation) at <1 nN forces with nanometric resolution.
  • Kelvin Probe Force Microscopy (KPFM): Maps electrostatic surface potential and work function.
  • TUNA/CAFM: Enables current mapping for electrical conductivity in semiconductors and nanomaterials.

These advanced modes enable multi-parameter surface mapping in a single scan, drastically improving data acquisition and analysis capabilities.

Applications of Atomic Force Microscopy by industry

Materials Science and Nanotechnology

AFM is pivotal in analyzing nanostructured materials, thin films, composites, and coatings. It provides:

  • High-resolution topographic maps.
  • Mechanical characterization (Young’s modulus, hardness, adhesion).
  • Analysis of wear and deformation under mechanical stress.

This information helps design advanced materials with tailored surface properties for aerospace, electronics, and energy applications.

Biomedical and Biosanitary applications

In biomedical research, AFM reveals cellular structures, measures membrane stiffness, and observes molecular binding forces in real-time. It is used to:

  • Differentiate between healthy and cancerous cells based on viscoelastic properties.
  • Study protein aggregation and receptor-ligand binding.
  • Investigate bacterial adhesion and extracellular matrix mechanics.

The ability of AFM to function in liquid environments is crucial for maintaining live cell conditions during measurements.

Semiconductor and Electronics

AFM is indispensable for analyzing surface defects, roughness, and conductive pathways at the nanometer level in integrated circuits (ICs), MEMS devices, and photovoltaic materials. Modes like KPFM and TUNA are used to:

  • Measure nanoscale electrical conductivity.
  • Characterize dielectric breakdown.
  • Map doping profiles.

Environmental and Surface Chemistry

AFM is increasingly applied to study microplastics, nanotoxicology, and pollutant detection in air, soil, and water. It is used to:

  • Visualize particle morphology.
  • Measure surface energy and adhesion.
  • Detect chemical functional groups with techniques like CFM and AFM-IR.

Comparative analysis: AFM vs. other microscopy and measurement techniques

TechniqueKey StrengthsLimitations
AFMNanoscale topography, mechanical & electrical analysis in ambient conditionsSlower scan speed, limited subsurface analysis
SEMHigh-resolution imaging of conductive materialsRequires vacuum and coating, limited for biological samples
TEMAtomic resolution, internal structure imagingExpensive, complex sample preparation
NanoindentationQuantitative mechanical propertiesLacks spatial resolution of AFM
Optical ProfilometryFast, non-contact surface mappingPoor vertical resolution below 100 nm

AFM stands out due to its versatility and resolution, especially when used for multi-modal surface characterization.

Challenges and barriers to adoption of AFM

Despite its advantages, AFM adoption faces several challenges:

  • High equipment costs: Advanced AFM systems are expensive, making them inaccessible for routine labs.
  • Complexity: Requires expert operators to run the system and interpret data.
  • Scanning time: Slower than optical or SEM techniques, especially for large areas.
  • Sample preparation: Soft or uneven samples may deform under probe interaction.
  • Data volume: Generates massive datasets that require sophisticated analysis tools.

Ongoing improvements in automation, software, and user interface design aim to lower these barriers and broaden AFM accessibility. More importantly, the use of expert personnel and speciallized facilities overcomes most of these drawbacks. To learn more, visit Unit 16 of NANBIOSIS: Surface Characterisation and Bacterial Colonization Unit.

Future trends and innovations in AFM

High-Speed AFM and automation

Emerging high-speed AFMs reduce scan times significantly, enabling near real-time visualization of dynamic biological and chemical processes. AI-powered analysis accelerates interpretation and enhances reproducibility.

AFM for Drug Delivery and molecular manipulation

AFM enables single-molecule force spectroscopy, critical in understanding drug-target interactions. In future applications, AFM-integrated tools could guide surgeries, diagnose diseases at the nanoscale, or evaluate drug responses in real time.

Integration with robotics and quantum research

Miniaturized AFM probes embedded in surgical instruments or autonomous robots could perform in vivo diagnostics. In quantum and nanoelectronics, AFM could help design next-generation devices with atomic precision.

Future enhancements may include:

  • AFM-endoscopy for cancer detection
  • AI-assisted materials discovery
  • Autonomous environmental nanosensors
  • Nanoassembly using functionalized probes

The adaptability of this technique makes it an ideal platform for multidisciplinary innovation.

Conclusion

Atomic Force Microscopy has evolved from a niche research tool to a multi-functional powerhouse in nanotechnology, biomedicine, electronics, and environmental science. With the ability to deliver atomic-scale resolution, multi-modal characterization, and operation under diverse conditions, AFM is shaping the future of materials research and nanoscale innovation.

Despite technical and financial barriers, ongoing developments in probe technology, high-speed scanning, and AI integration are making AFM more accessible and efficient than ever. From studying living cells to engineering quantum devices, AFM is, and will remain, one of the most transformative tools in modern science.

Credits:
Margarita Hierro Oliva
Gabriel Alfranca

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

HPLC: What It Is, How It Works, and Its Applications in Modern Biotech

Discover what HPLC is, how it works, and why it’s essential in analytical chemistry and biotechnology. Learn about real applications like LC/MSD iQ integration for antibody purification.

What is HPLC? Understanding High-Performance Liquid Chromatography

High-Performance Liquid Chromatography (HPLC) is one of the most powerful analytical techniques used in chemistry, biochemistry, and biotechnology. From pharmaceutical quality control to the purification of cutting-edge biotechnological products, HPLC provides high-resolution separation and precise quantification of complex mixtures. Its precision, sensitivity, and versatility have made it indispensable in both research and industrial settings.

This article explores how HPLC works, its key components, real-world applications —including the integration of mass detectors like the Agilent LC/MSD iQ— and how this technique is evolving toward automation and AI-enhanced scalability.

How does HPLC work? Core principles and mechanism

At its core, HPLC is a technique for separating, identifying, and quantifying the components of a mixture by exploiting their interaction with a stationary phase and a liquid mobile phase under high pressure.

Mobile and stationary phases

The mobile phase is a liquid solvent or a mixture of solvents that carries the sample through the system. The stationary phase is typically a column packed with small, porous particles (often silica-based) that interact differently with each compound.

As the mobile phase flows under high pressure through the stationary phase, each component in the sample moves at a different rate depending on its chemical characteristics and interaction with the column material.

Retention time and elution

Every compound elutes from the column at a different retention time. This is a key indicator used to identify and quantify substances. The sharper and more distinct the elution peaks, the more effective the separation.

Types of HPLC

HPLC can be tailored to different applications through various modes:

  • Isocratic Elution: A constant mobile phase composition throughout the run.
  • Gradient Elution: Varies the composition of the mobile phase to improve separation of complex mixtures.
  • Reverse-Phase HPLC (RP-HPLC): The most common form, using a nonpolar stationary phase and polar mobile phase.
  • Normal-Phase HPLC, Ion-Exchange HPLC, and Size-Exclusion HPLC are also used based on the molecular properties of the analytes.

Key components of an HPLC system

Understanding each part of the system is essential for appreciating its versatility and precision, as well as to help understanding how it can benefit from the analytical potential of this technique.

1. Solvent delivery system (Pump)

The pump delivers the mobile phase through the column at a precise and constant flow rate, often between 0.5 to 1.5 mL/min, under pressures of up to 6000 psi.

2. Injector and sample introduction

The injector introduces the sample into the mobile phase. Manual or autosampler injectors are used depending on the system’s automation level. This provides the column with a mixture of the sample and the mobile phase.

3. Column: The Heart of HPLC

This is where the separation happens. Columns vary in length, diameter, and particle size depending on the application. Different types of columns can be used depending on the nature of the sample. Reverse-phase C18 columns are the most widely used in pharmaceutical and biotech labs.

4. Detectors: UV vs Mass Spectrometry (MS)

Traditional systems use UV-Vis detectors to measure absorbance. However, newer systems incorporate Mass Spectrometry (LC-MS) for enhanced specificity. Mass detectors can identify compounds based on molecular weight, offering far superior sensitivity and selectivity.

HPLC vs LC-MS: Enhanced analytical power

Combining HPLC with Mass Spectrometry (LC-MS) brings unmatched analytical power, especially when dealing with complex biological samples. This is thanks to their superior analytical capabilities compared to traditional detection approaches.

The role of LC/MSD iQ integration

At NANBIOSIS Unit 2 (CAbS), researchers have integrated the Agilent G6160A LC/MSD iQ mass selective detector with the Agilent 1260 HPLC system to significantly enhance immunoreagent analysis.

This configuration enables:

  • Specific molecular mass detection
  • Rapid confirmation of compound identity
  • Higher selectivity than UV detectors, even for overlapping peaks
  • Improved purification protocols

Advantages over traditional UV detection

Traditional UV detectors may struggle with closely eluting or co-eluting compounds, especially in bioanalytical samples. LC-MS eliminates this by providing a mass fingerprint for each analyte, ensuring better resolution and reducing false positives.

Real Case: Immunoreagent characterization

NANBIOSIS experts at Unit 2 (Custom Antibody Service) use LC/MSD iQ for:

  • Monitoring the purity of antibodies
  • Quantifying specific immunoreagents
  • Characterizing molecular forms for regulatory compliance

This setup supports biotech development pipelines and technology transfer from lab to industry, highlighting the practical utility of this cutting-edge analytical technique.

Applications of HPLC in science and the industry

HPLC is essential across multiple fields where chemical precision is non-negotiable. A few examples are listed herein.

Pharmaceutical Analysis and Quality Control

  • Identification and quantification of active pharmaceutical ingredients (APIs)
  • Stability testing and degradation analysis
  • Regulatory compliance (FDA, EMA)

Biotechnology and Biologics Purification

  • Purification of monoclonal antibodies, peptides, and recombinant proteins
  • Analytical development for biosimilars and biobetters
  • Batch release testing in biomanufacturing

Environmental and Food Safety Testing

  • Detection of contaminants, pesticides, or drug residues
  • Analysis of food additives, vitamins, and preservatives
  • Monitoring of water quality and industrial effluents

Advantages and limitations of HPLC

Strengths

  • High precision and reproducibility
  • Exceptional resolution of complex mixtures
  • Compatibility with a wide range of detectors and samples
  • Scalable from analytical to preparative scales

Limitations

  • High equipment and maintenance cost
  • Requirement of trained personnel
  • Complex method development
  • Solvent usage and disposal issues

These limitations, however, are mitigated in advanced laboratories through automation, SOPs, and proper training protocols. This is where NANBIOSIS Unit 2 can help you overcome these hurdles.

Future of HPLC: Innovation and automation

There are a few ground-breaking technologies that can potentially revolutionize many analyticial techniques, and HPLC is no exception. The integration of AI, robotics, and cloud-based systems is redefining what HPLC can do.

AI-integrated HPLC platforms

Future systems could incorporate real-time predictive analytics, optimizing flow rates, gradients, and detection settings for maximum efficiency.

Large-scale applications and process control

With sufficient investment, platforms like Agilent LC/MSD iQ can be scaled for industrial-level purification, maintaining accuracy without manual intervention.

Vision from CAbS: NANBIOSIS Expertise

In a scenario with unlimited funding, the team at NANBIOSIS Unit 2 envisions:

  • A fully integrated LC/MS-AI platform
  • Real-time monitoring and adaptive process control
  • Seamless tech transfer from lab to industrial production
  • Global-scale immunoreagent production with full traceability

This would elevate the role of HPLC from an analytical tool to a core component of industrial bioprocessing infrastructure.

Conclusion: Why HPLC remains indispensable in Analytical Chemistry

Despite the emergence of newer techniques, HPLC remains the gold standard for separation science. Its adaptability —especially when combined with mass spectrometry— ensures its place in the future of biotech, pharma, and beyond.

Whether you’re developing life-saving biologics, ensuring water safety, or refining analytical workflows, HPLC continues to deliver unmatched resolution, reliability, and reproducibility.

Credits:
Nuria Pascual
Gabriel Alfranca

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Understanding Zeta Potential: Surface Charge at the Solid/Water Interface and Its Role in Modern Materials Science

Explore the importance of zeta potential and surface charge at the solid/liquid interface for biomaterials, membranes, and nanomaterials.

What is Zeta Potential and why does it matter?

Zeta potential is a key physicochemical parameter that describes the electrostatic potential at the slipping plane of a solid surface in a liquid medium. It is not a direct measure of surface charge but rather the potential at the boundary between the stationary layer of fluid attached to the surface and the mobile layer of the surrounding liquid. This parameter is crucial for understanding the behavior of colloidal dispersions, emulsions, and particles in suspension.

The phenomenon of zeta potential emerges from the formation of the electrical double layer (EDL) at the interface between a solid and an aqueous solution. This layer consists of a charged surface and a compensating layer of counter-ions. When an external field is applied, the movement of these ions relative to the surface creates an observable potential difference.

Zeta potential impacts the stability of colloidal systems: high absolute values (positive or negative) indicate strong electrostatic repulsion, which helps prevent aggregation. Conversely, low values may signal a risk of flocculation or sedimentation. Hence, it is a critical metric in formulating stable suspensions in pharmaceuticals, cosmetics, food products, and beyond.

Surface charge at the solid/water interface

The solid/water interface is a dynamic region where charge develops due to several mechanisms: ionization of surface groups, ion adsorption, and lattice defects. The type and density of surface charge depend strongly on pH, ionic strength, and the nature of the surrounding electrolyte.

This surface charge is the origin of the electrical double layer and directly influences interactions with dissolved molecules, proteins, or ions. In biological and environmental systems, it governs key processes such as adsorption, desorption, ion exchange, and membrane transport.

In materials science, understanding surface charge is essential for tailoring materials with desired wettability, adhesion, or biocompatibility. This is especially relevant in applications involving membranes, coatings, and nanostructures that operate in aqueous environments.

How Zeta Potential is measured: techniques and technologies

Several techniques are used to determine zeta potential, including electrophoretic light scattering (ELS) for colloidal systems and streaming potential or streaming current methods for solid surfaces. Among advanced tools, the SurPASS 3 Electrokinetic Analyzer stands out for its ability to directly measure the zeta potential at the solid/liquid interface.

SurPASS 3 uses the classical electrokinetic approach with continuous flow: an electrolyte is passed through a channel formed between the sample surface and a reference, and the resulting flow potential or flow current is measured. This allows for precise, non-destructive analysis of a wide variety of sample geometries, including flat surfaces, powders, fibers, and porous materials.

Moreover, SurPASS 3 integrates automated pH titration using syringe pumps, enabling the determination of the isoelectric point (IEP). This is invaluable for tracking surface modifications and understanding material behavior across different pH levels. This equipment is available in the services of our Unit 16, among other surface characterization techniques.

Key applications across industries

Biomedical and Pharmaceutical

  • Implants: Evaluation of surface charge helps optimize biocompatibility and reduce immune rejection.
  • Drug delivery: Zeta potential measurements inform the design of nanoparticle carriers to enhance targeting and stability.
  • Contact lenses: Assessment of protein adsorption through surface charge analysis supports development of more comfortable and hygienic lenses.

Materials science and engineering

  • Membrane characterization: Understanding surface charge assists in improving antifouling properties and selectivity.
  • Nanomaterial design: Enables engineering of coatings like graphene oxide with specific interfacial behaviors.
  • Coating and adhesion studies: Surface charge insights guide the functionalization and durability of advanced materials.

Environmental and energy applications

  • Fuel cell membranes: Characterizing zeta potential supports optimization of ion transport layers.
  • Water purification: Adsorbent and filter materials benefit from surface charge tuning for enhanced contaminant removal.

Industrial and commercial uses

  • Textile finishing: Zeta analysis supports better dyeing, treatment, and functional coatings.
  • Food packaging: Helps in developing antimicrobial or oxygen-barrier films.
  • Construction materials: Surface property evaluation leads to more durable and weather-resistant materials.

Competitive edge of SurPASS 3 vs other equipment

Compared to traditional surface analysis equipment, SurPASS 3 offers:

  • Automation: Rapid, reproducible results with minimal user intervention.
  • Versatility: Accommodates diverse sample shapes and sizes.
  • pH-dependent profiling: Automatically determines IEP and adsorption/desorption kinetics.
  • Real-time monitoring: Enables observation of surface transformations during chemical treatments.

However, barriers exist:

  • Sample requirements: Specific geometries and physical properties are needed.
  • Infrastructure needs: Compressed nitrogen supply and optional temperature control increase setup costs.
  • Technical expertise: Trained operators are essential for accurate interpretation and maintenance.

Future outlook: emerging and visionary applications

In the near term, SurPASS 3 will continue supporting:

  • Real-time adsorption studies for R&D
  • Surface engineering of biomaterials
  • Environmental material design (e.g., photocatalysts, adsorbents)

Long-term applications include:

  • 4D-printed responsive materials with programmed zeta profiles
  • Nanomaterials for quantum devices with controlled interfacial properties
  • Virus-trapping smart surfaces for healthcare settings
  • Carbon capture materials using charge-optimized MOFs

Final thoughts: why Zeta Potential is a foundational metric

Zeta potential is not just a measurement—it’s a gateway to understanding how materials behave at the most fundamental level. From drug delivery to environmental technology, from textile innovation to nanotechnology, the surface charge at the solid/liquid interface defines interactions, stability, and performance.

With tools like the SurPASS 3, researchers and engineers can now explore these properties with unmatched precision and adaptability, paving the way for smarter, more functional materials.

Credits:
Margarita Hierro Oliva
Gabriel Alfranca

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Protein Purification Methods: Advanced Techniques and Automation with ÄKTA Pure

Explore modern protein purification methods with a special focus on automated systems like ÄKTA Pure. Learn how advanced chromatography workflows are transforming antibody production, diagnostics, and biotech applications.

What is protein purification and why does it matter?

Protein purification is a fundamental process in biotechnology, biomedical research, and pharmaceutical production. It involves isolating a specific protein of interest from a complex mixture, such as a cell lysate, while preserving its structure and function. This process is critical because the quality, purity, and yield of proteins directly impact downstream applications such as drug development, diagnostic assays, and therapeutic research.

In the context of immunoreagents, such as antibodies, protein purification ensures the removal of host cell proteins, nucleic acids, and other contaminants that may interfere with analytical or clinical performance. High-purity proteins are essential for reproducibility and reliability across scientific studies.

The traditional steps of protein purification

The protein purification workflow typically includes several key steps:

  1. Cell lysis and extraction: Disruption of the cell membrane to release intracellular contents using chemical, mechanical, or enzymatic methods.
  2. Clarification: Removal of insoluble debris through centrifugation or filtration.
  3. Buffer exchange and conditioning: Adjusting pH, salt concentration, and adding stabilizers to optimize protein behavior before chromatography.

Each step requires careful design to avoid loss of protein function or yield.

Overview of core purification techniques

Several chromatographic methods are widely employed:

  • Affinity Chromatography: Exploits specific interactions between the protein and a ligand attached to a resin. Protein A or G resins are commonly used for antibody purification.
  • Ion Exchange Chromatography (IEX): Separates proteins based on charge differences.
  • Size Exclusion Chromatography (SEC): Also known as gel filtration, this method separates proteins based on size and shape.
  • Precipitation and Filtration: Less specific methods used in early-stage purification, often resulting in variable quality.

The role of automation in protein purification: ÄKTA Pure

The ÄKTA Pure system represents a shift towards automation in protein purification. Developed by Cytiva, it integrates multiple chromatography techniques into a single, modular, and highly customizable platform.

ÄKTA Pure addresses key challenges in protein purification:

  • Reproducibility: Reduces variability associated with manual processes.
  • Contamination Control: Automation minimizes exposure and potential degradation.
  • Optimization: Through UNICORN software, parameters like flow rate, pH, and gradient elution are finely controlled.

Its use of affinity, ion exchange, and size exclusion chromatography enables highly pure antibody isolation with reduced time and effort.

Comparative analysis: ÄKTA Pure vs other systems

While traditional systems like HPLC offer precision, they lack the flexibility and ease of method development found in ÄKTA Pure. Manual purification methods, although accessible, introduce variability and limit scalability.

Compared to other FPLC systems, ÄKTA Pure stands out due to:

  • Integrated software (UNICORN) for intuitive protocol design
  • Modular components for flexibility
  • Scalability from research to pilot production

Applications and impact in the biomedical and biotech industries

The ÄKTA Pure system has a significant impact in fields requiring consistent, high-purity proteins:

  • Diagnostics: Antibody production for ELISA and lateral flow assays
  • Biotech R&D: Reliable protein reagents for drug screening and discovery
  • Therapeutics: Preparation of immunoreagents for preclinical validation

Barriers to entry and practical considerations

Despite its advantages, implementing ÄKTA Pure may involve high initial equipment cost, training needs for advanced chromatography and software use, and infrastructure adjustments in existing labs.

However, these challenges are offset by long-term gains in quality, throughput, and compliance.

Near and long-term opportunities for automated protein purification

Short and mid-term applications include:

  • Routine antibody purification for biomedical research
  • Development of high-performance diagnostic reagents
  • Protocol refinement to increase yields and consistency

Looking forward:

  • Integration with AI for adaptive protocol optimization
  • Large-scale purification of advanced antibody formats (e.g., bispecifics, ADCs)
  • Continuous processing for industrial-scale immunoreagent production

NANBIOSIS case study: Integrating ÄKTA Pure into CABS services

The CABS platform within NANBIOSIS incorporates ÄKTA Pure to support:

  • Rapid adaptation to different antibody types
  • Regulatory-compliant workflows
  • Expert-guided optimization for diverse client needs

This integration allows seamless transition from research protocols to industrial applications, drastically decreasing the challenges of the technique, and enhancing efficiency and reliability.

Conclusion

Modern protein purification is evolving from manual methods to intelligent, automated systems. ÄKTA Pure exemplifies this shift, offering robust solutions to common challenges in protein production. As the demand for high-quality immunoreagents grows, adopting flexible, scalable purification systems will be key to innovation in diagnostics, therapeutics, and beyond.

Credits:
Nuria Pascual
Gabriel Alfranca

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Advances in MRI and Brain Tumor Imaging: NANBIOSIS at ISMRM 2025

NANBIOSIS Unit 25 showcased preclinical MRI advances at ISMRM 2025 Iberian Chapter with talks, posters, and international collaboration.

Barcelona, July 8, 2025NANBIOSIS Unit 25: NMR: Biomedical Applications I, played a leading role at the 5th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), Iberian Chapter, held on July 3–4 at the Institute for Bioengineering of Catalonia (IBEC). The event brought together top researchers in Magnetic Resonance Imaging (MRI) and Nuclear Magnetic Resonance (NMR) from Spain and Portugal, highlighting cutting-edge applications in preclinical imaging and biomedical research.

Strong Scientific and Organizational Presence from NANBIOSIS

Researchers from Unit 25 of NANBIOSIS, a key platform for NMR-based biomedical applications at the Universitat Autònoma de Barcelona (UAB), made major contributions to the scientific program. Dr. Ana Paula Candiota, Scientific Director, and Dr. Silvia Lope-Piedrafita, Scientific Coordinator, were both members of the local organizing committee and actively participated in the scientific sessions.

Silvia Lope during her talk “Applying longitudinal MRI for tumor evaluation in two immunocompetent chicken chorioallantoic membrane (CAM) cancer xenograft models”.

Dr. Lope-Piedrafita gave an oral presentation titled “Applying longitudinal MRI for tumor evaluation in two immunocompetent chicken chorioallantoic membrane (CAM) cancer xenograft models,” showcasing innovative imaging approaches in oncology research. The study was co-authored by Dr. Candiota.

Dr. Ana Paula Candiota in one of her three poster pitches: “Bridging 3T and 7T MR: Towards Unified Metabolic Profiling for Preclinical Brain Tumor Studies”.

Dr. Candiota also delivered three poster pitches, including “Bridging 3T and 7T MR: Towards Unified Metabolic Profiling for Preclinical Brain Tumor Studies.” Part of this research was conducted during her CIBER-funded scientific mobility stay in Portugal, reflecting ongoing international collaboration within the network.

About Unit 25: Advanced NMR Tools for Biomedical Applications

Unit 25 of NANBIOSIS is a unique research infrastructure offering in vivo, ex vivo, and in vitro NMR services. It is jointly operated by the Nuclear Magnetic Resonance Facility (SeRMN) and the Institute of Biotechnology and Biomedicine (IBB) at UAB, and coordinated by Dr. Candiota herself.

This infrastructure enables high-resolution molecular imaging, metabolic profiling, and biomarker discovery for translational research in oncology, neurology, and other biomedical fields. For more information about the Unit, you can visit the portfolio here.

Promoting Innovation in Magnetic Resonance Imaging

The participation of NANBIOSIS U25 in the ISMRM 2025 Iberian Chapter meeting reinforces its role as a national and international reference in the development and application of NMR and MRI technologies for biomedical research and preclinical trials. For further details about the event, visit the official ISMRM Iberian Chapter site.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Researchers develop a promising therapy for alcohol‑induced brain injury thanks to NANBIOSIS services

First study using NANBIOSIS Unit 26 PET/MRI‑3T shows MSC-EVs reduce alcohol-induced brain damage and neuroinflammation in female mice.

Valencia, Spain – The Spanish national infrastructure NANBIOSIS is celebrating a significant breakthrough: the first scientific article utilizing PET/MRI‑3T imaging services from Unit 26 has been published, showcasing a novel therapy against alcohol-induced brain damage in female mice.

Study overview & key findings

The article, titled “Role of miRNAs from mesenchymal stem cell‑derived extracellular vesicles in neuroinflammation and behavioral impairments induced by chronic alcohol consumption in female mice“, appeared online ahead of print in Neural Regeneration Research on June 19, 2025 . It demonstrates that repeated intravenous doses of mesenchymal stem cell-derived extracellular vesicles (MSC‑EVs), rich in regulatory miRNAs, effectively:

  • Reduced alcoholism-driven neuroinflammation, confirmed by lower expression of pro-inflammatory genes like Tnf, Il1b, Mtor and Atf6
  • Improved cognitive behavior and attenuated sensitivity to cocaine’s conditioned reward
  • Decreased abnormal brain glucose metabolism, shown via reduced uptake of the PET tracer ^18F-FDG

Role of PET/MRI‑3T Imaging from NANBIOSIS

This milestone became possible thanks to the recently launched PET/MRI‑3T platform of Unit 26: a state-of-the-art preclinical imaging system combining a 3 Tesla MRI with integrated PET capabilities. This dual-modality setup enables precise metabolic and anatomical visualization in vivo, allowing researchers to perform longitudinal studies in small rodents. In this case, the imaging revealed a reversal of ethanol-induced metabolic dysregulation in the brains of treated mice.

Graphical abstract of the publication. Reproduced with permission from the publisher (link).

The relevance of these findings

These results provide compelling in vivo evidence that miRNA-enriched MSC-EVs can counteract alcohol-induced brain damage. In addition, it etablishes NANBIOSIS Unit 26 as a leader in multimodal preclinical imaging, bridging molecular insights with live metabolic data. Finally, this research opens new avenues for research in neuroscience, regenerative medicine, and addiction therapy.

About NANBIOSIS Unit 26

Housed at the Faculty of Medicine at University of Valencia, NANBIOSIS Unit 26 is led by Dr. Ramón Martínez Máñez (UPV) and Dr. Salvador Gil (UV-SCSIE). Beyond the PET/MRI‑3T, the Unit offers, among other services, a 14 Tesla NMR spectrometer for ex vivo metabolic profiling and advanced support for in vivo and ex vivo metabolic and molecular imaging in rodents.

Strategic impact and future directions

This publication not only highlights the scientific value of MSC-EV therapy for alcohol-related neuroinflammation but also spotlights NANBIOSIS imaging capabilities. Future research leveraging this infrastructure could revolutionize fields such as neuropharmacology, regenerative medicine, and translational research, thanks to its ability to bridge preclinical data to human therapies.


Access the full article: see Neural Regeneration Research, June 19, 2025, doi:10.4103/NRR.NRR‑D‑24‑01260

And do not forget that our last Open Call of 2025 is open until June 30. Visit here for more information.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Prof. Jesús Santamaría secures his third ERC Advanced Grant in tumor-targeting nanomedicine

Prof. Jesús Santamaría wins his third ERC Advanced Grant for a €3.1M project to boost tumor targeting in nanomedicine.

Zaragoza, 23 June 2025 – Prof. Jesús Santamaría, Chair of Chemical Engineering at the University of Zaragoza and Scientific Director of NANBIOSIS Unit 9, has been awarded his third European Research Council (ERC) Advanced Grant—a rare achievement shared by only five other researchers in Spain, as reported in the official Unizar webpage.

The newly funded project, ROMEO (“Cracking the code on tumor targeting with nanostructures: competitive kinetics and extracellular vesicles“), will receive €3.12 million over five years, exceeding the usual €2.5 million cap thanks to supplemental funding for major equipment.

ROMEO was selected among 281 proposals out of 2,534 submissions in the 2024 ERC Advanced Grant competition, under the Horizon Europe programme. The total ERC funding amounted to €721 million, with only 14 grants awarded to Spanish researchers.

Pioneering Strategies to Boost Tumor Nanoparticle Delivery

Despite decades of research, less than 1% of systemically administered nanoparticles reach tumors; up to 95% are sequestered by liver macrophages. The ROMEO project aims to overcome this barrier using:

  1. Competitive kinetics: designing “decoy” particles that pre‐saturate macrophages, reallocating therapeutic nanoparticles toward tumors.
  2. Extracellular vesicle (EV) vectors: employing tumor‑derived EVs that naturally home to their tissue of origin as targeted delivery vehicles.

The research will be led at INMA (CSIC‑Unizar) and IIS Aragón with a multidisciplinary team extending across chemistry, materials, and biology, including collaborators from I3A and IQAC‑CSIC in Barcelona.

A stellar record of excellence

The expertise of Prof. Santamaría in nanomaterials is well‑recognized: over 385 publications, 26 patents, leadership in 101 research initiatives (20 European-funded), and supervision of 39 PhD theses. Within the ERC framework, his grant history includes:

  • HECTOR (2011, €1.85 M): Microwave‑activated catalytic microreactors.
  • CADENCE (2017, €2.45 M): Tumor‑targeted catalytic therapy via in situ activation.
  • ROMEO (2025, €3.12 M): Nanostructure and EV–based tumor targeting.

With total ERC Advanced Grant funding exceeding €7.4 million, his sustained success contributes to the University of Zaragoza’s tally of 20 ERC projects (€34.8 M total) since 2009.

NANBIOSIS Unit 9: A key driver in Translational Nanomedicine

As Scientific Director of NANBIOSIS Unit 9 – Synthesis of Nanoparticles, Santamaría oversees an advanced laser‑induced pyrolysis platform producing large quantities of hybrid, biocompatible nanoparticles. This Unit supports automated synthesis, comprehensive physicochemical characterization, and preclinical testing—making it a hub for both academic and industrial R&D in nanomedicine.

Unit 9 (U9) is part of the Nanostructured Films and Particles Group at INMA (CSIC‑Unizar), located at Campus Río Ebro, Zaragoza, with capabilities in microstructural, optical, magnetic, and functional analysis of nanoparticles.

And do not forget that our last Open Call of 2025 is open until June 30. Visit here for more information.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Discover the latest Biomedical Imaging and Metabolomics equipment at NANBIOSIS platforms

Seminar on imaging and metabolomics platforms at UV, featuring NANBIOSIS equipment and recent biomedical research applications.

Valencia, June 2025 — Researchers and clinicians interested in cutting-edge preclinical imaging and metabolomics technologies are invited to attend the upcoming seminar “Biomedical and Metabolomic Imaging Section: Equipment and Applications”, taking place on Friday, June 27, 2025, at 13:00, in Seminar Room D, Faculty of Medicine and Dentistry, Universitat de València.

The seminar will be delivered by Mustafa Ezzeddin Ayoub (“Musta”), technical expert from the Biomedical and Metabolomic Imaging Section at the University Clinical Hospital of Valencia (UCIM). The session will provide a comprehensive overview of the high-performance imaging and metabolomics equipment available at the facility, with special emphasis on NANBIOSIS Unit 26 – NMR Biomedical Applications II.

Key imaging technologies featured:

  • MRI 3 Tesla (MR Solutions) – Advanced preclinical magnetic resonance imaging system for high-resolution in vivo studies.
  • PET/CT Scanner – Hybrid positron emission tomography and computed tomography system used in translational research for cancer, neuroscience, and cardiovascular diseases.
  • IVIS Imaging System – Optical imaging for bioluminescence and fluorescence in small animal models.
  • Irradiator – Preclinical tool for targeted radiobiology experiments.

Metabolomics platform featured:

  • 600 MHz Vertical NMR Spectrometer – Essential for metabolomic profiling, biomarker discovery, and metabolic flux analysis in both clinical and preclinical research.

This event will highlight recent equipment upgrades, new research applications, and the scientific capabilities that these platforms bring to biomedical research. Over the past 3-4 years, these instruments have supported a wide range of in vivo and ex vivo applications, contributing to numerous scientific projects in collaboration with academia and the private industry.

Although the seminar is in-person only, the presentation materials will be made available online (in this same webpage) for those interested in learning more about the imaging and metabolomics capabilities supported by NANBIOSIS.

And if you want to collaborate with us, do not forget that our Open Call is due on June 30! You can find more information here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

NANBIOSIS U6 organizes a seminar on Isothermal Titration Microcalorimetry in collaboration with IESMAT

Join NANBIOSIS and IESMAT on June 10 for a seminar on microcalorimetry with live demos and expert insights at ICMAB & online.

Date: Tuesday, 10 June 2025
Time: 9:30 AM – 12:00 PM
Location: Sala d’Actes Carles Miravitlles, ICMAB-CSIC & Online
Organized by: Unit 6 of NANBIOSIS (U6 Preparation and characterization of nano- and microstructured molecular soft materials – Soft Materials Service)
In collaboration with: IESMAT

Barcelona, june 2025. NANBIOSIS Unit 6 is pleased to invite researchers, professionals, and students to the upcoming Technical Seminar on Isothermal Valoration Microcalorimetry, organized in collaboration with IESMAT and hosted at the Institute of Materials Science of Barcelona (ICMAB-CSIC).

This theoretical and practical seminar will take place on Tuesday, 10 June 2025, from 9:30 AM to 12:00 PM, offering both in-person and online participation options.

Welcome to a Journey into Thermal and Energetic Analysis

Microcalorimetry has become a powerful technique for characterizing materials through their thermal properties and molecular interactions. This seminar aims to provide both a conceptual and hands-on understanding of the use of Isothermal Titration Calorimetry (ITC) in scientific research and industrial applications.

Seminar Highlights

  • 9:30–10:00Presentation of SOFT/U6 NANBIOSIS Services: Learn about the advanced characterization capabilities and collaborative opportunities offered by Unit 6.
  • 10:00–11:00Isothermal Titration Microcalorimetry: A Versatile Tool for Understanding Molecular Interactions: Dive into the principles, applications, and advantages of ITC in materials science and biomedical research.
  • 11:00–12:00Live Demonstration with Peaq-ITC: A hands-on session led by a Malvern Panalytical specialist, featuring real-time measurements and interaction with state-of-the-art equipment.

Why Attend?

  • Gain insight into how microcalorimetry contributes to the development and evaluation of advanced materials.
  • Engage directly with experts and discover real-world applications.
  • Expand your network in the field of material characterization.

Register now to attend in person or follow the seminar online!
👉 [Register here]

For more information about NANBIOSIS U6 and upcoming activities, visit: https://www.nanbiosis.es/portfolio/u6-soft-materials-service/


This event is part of NANBIOSIS’ ongoing commitment to support scientific excellence and promote access to cutting-edge technologies in biomedical and materials research.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Event recap: “Fabry Connections” brings together science and patients at ICMAB

“Fabry Connections” united patients, researchers, and clinicians at ICMAB to advance Fabry disease care and nanomedicine-based therapies.

Barcelona, april 2025. On Tuesday, 29 April 2025, the Institute of Materials Science of Barcelona (ICMAB, CSIC) hosted the event “Fabry Connections: Science, Patients, and Future”, bringing together around 50 participants including researchers, clinicians, patients, and patient association representatives. The event aimed to create a multidisciplinary platform for sharing knowledge and advancing the future of Fabry disease research and treatment.

Attendees at the Fabry Connections event at ICMAB | ICMAB-CSIC

As we announced back in february 28, this special event was held within Fabry Disease Awareness Month (April) and is part of the European Innovation Council (EIC) Nano4Rare project, which focuses on developing nanomedicine-based therapies for Fabry disease. Despite uncertainty caused by a blackout the day before, the event was held as planned—thanks to the commitment and flexibility of all speakers and participants.

Guillem Pintos during the Fabry event | ICMAB-CSIC

Building bridges between science and patients

The day opened with welcoming words by Lourdes Fàbrega, Director of ICMAB, and Nora Ventosa, coordinator of the Nano4Rare project (together with Elisabet González, Scientific Coordinator of Unit 6), who emphasized the importance of organizing events that foster dialogue between researchers, clinicians, and patients. Throughout the day, the program featured insightful keynote lectures by Guillem Pintos (Vall d’Hebron Hospital), Maria Camprodon (Vall d’Hebron Hospital), and Sílvia Muro (IBEC), highlighting the evolution of Fabry disease diagnosis and treatment, and exploring future therapeutic approaches including advanced nanomedicine.

Roundtable with Simó Schwartz, Maria Camprodon, Jordi Cruz, Alfredo Romero (patient) moderated by Guillem Pintos | ICMAB-CSIC

Centering the patient experience

One of the central themes of the event was the importance of patient-centered approaches in rare disease research and care. This was strongly emphasized during the roundtable discussions, where speakers discussed the need for early diagnosis, stronger collaborative networks, and patient inclusion in the research process.

A first roundtable on the importance of diagnosis included a Fabry patient, Alfredo Romero, and Simó Schwartz (Vall d’Hebron Hospital), Maria Camprodon (Vall d’Hebron Hospital), Jordi Cruz (MPS Lisosomales and FEDER foundation ) and was moderated by Guillem Pintos (Vall d’Hebron Hospital). A second roundtalbe, in the afteroon, was devoted to R+D challenges on LSD diseases and was moderated by Judit Tomsen (ICMAB-CSIC) and included the participation of Sílvia Muro (IBEC), Míriam Royo (IQAC-CSIC) and Ibane Abasolo (IQAC-CSIC). 

Jordi Cruz, Director of MPS Lisosomales and board member of FEDER, and Francesc Cayuela, President of the Catalan Federation of Rare Diseases (FECAMM), both underlined the vital role of patient organizations in supporting affected individuals and giving visibility to rare conditions. 

Elisabet Gonzàlez presenting the Nano4Rare project at the Fabry event | ICMAB-CSIC 

A look at research and innovation

The program included the presentation of the Nano4Rare project (EIC Transition) by Elisabet Gonzàlez, researcher at the Nanomol-Bio Group (ICMAB-CSIC) and coordinator of the Nano4Rare project, together with Nora Ventosa, both in Unit 6 of NANBIOSIS, as well as the presentation of the NEX-TRY project (ISCIII Instituto de Salud Carlos III) by Ibane Abasolo, leader of the Therapeutic Applications of Nanomedicine Research Group at IQAC-CSIC and Scientific Director of Unit 20. These sessions highlighted ongoing efforts to develop innovative therapies for Fabry disease and other rare conditions using advanced nanomedicine approaches. 

Attendees had the opportunity to network and exchange ideas during the coffee break and lunch sessions, which counted with wonderful dishes and was a time to enjoy and reflect. 

The event concluded with a guided visit to Nanomol Technologies, located at the UAB Campus, where participants toured the pilot plant for nanomedicine production, gaining a first-hand look at how research is being translated into therapeutic innovation.

Roundtable with Sílvia Muro, Míriam Royo (Unit 3), Ibane Abasolo (Unit 20) moderated by Judit Tomsen | ICMAB-CSIC

Looking ahead

The “Fabry Connections” event was a vivid reminder of the power of collaboration across disciplines. It highlighted how research centers like ICMAB can become vital spaces where patients, scientists, clinicians, and associations come together to inspire progress and co-create a better future for people affected by rare diseases.

We thank all participants, speakers, and supporters for making this event possible and reaffirm our commitment to advancing research, raising awareness, and supporting the rare disease community.

Visit at Nanomol Technologies | ICMAB-CSIC

About Nano4Rare

Nano4Rare is a European research project focused on the preclinical development of a nanomedicine candidate for Fabry disease treatment, aiming for clinical application. Nano4Rare is a European Innovation Council (EIC) Transition project, a program aimed for the validation of technologies and the development of business plans for specific applications (TRL 3-6). The project is coordinated by Nora Ventosa and Elisabet González, researchers at the Nanomol-Bio group at ICMAB-CSIC, and is linked to the Phoenix OITB EU project (Pharmaceutical Open Innovation Test Bed for Enabling Nano-pharmaceutical Innovative Products). 

NANBIOSIS participation

Several members of NANBIOSIS actively participated in the “Fabry Connections” event at ICMAB. Representing Unit 6, Prof. Nora Ventosa and Dr. Elisabet González presented the Nano4Rare project. Unit 6 specializes in the development, characterization, and scale-up production of molecular biomaterials with controlled nano- and supramolecular structure using compressed fluid-based technologies. Also present was Dr. Ibane Abasolo, Scientific Director of Unit 20, which offers preclinical validation of therapeutic compounds and biomarkers using advanced in vivo imaging and animal models. From Unit 3, Dr. Miriam Royo participated in a roundtable discussion on R&D challenges in lysosomal storage diseases; this Unit focuses on the synthesis, purification, and modification of bioactive peptides for therapeutic applications. Lastly, researchers from Unit 1, the Protein Production Platform (PPP), were also in attendance, such as José Luis Corchero. This Unit provides tailored services for the design, production, and purification of recombinant proteins using prokaryotic and eukaryotic systems. Together, these Units showcased NANBIOSIS’ multidisciplinary capabilities in advancing nanomedicine for rare diseases like Fabry.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More